Silver Lining: Will GSK Case Increase Compliance In China?
This article was originally published in PharmAsia News
Executive Summary
Although it promises to be a bumpy road, the GSK investigation could lead to a more compliant health care industry with Chinese anti-bribery laws acting as a more forceful deterrent to local players than the U.S. Foreign Corrupt Practices Act.
You may also be interested in...
GSK’s DoJ Settlement Requires Execs To Forfeit Bonuses If Misconduct Occurs
GlaxoSmithKline pleads guilty to promoting Paxil and Wellbutrin off-label and failing to report Avandia safety data to FDA; civil portion of settlement resolves off-label and kickback allegations involving nine products. New corporate integrity agreement gives OIG authority to require a recall.
China Executes Former Food And Drug Head
China executed Zheng Xiaouy, the former head of the State Food and Drug Administration, July 10 for dereliction of duty and for accepting $850,000 worth of bribes from pharmaceutical companies, according to the official Xinhua news service
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.